0 items
September 21, 2022 — Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the provisional ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
-
-
May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD) study were presented as late-breaking clinical research ...
-
February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). The ...
-
June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery disease (PAD) revascularization with paclitaxel drug-coated devices. This ...
September 21, 2022
July 5, 2022 — A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and ...
July 05, 2022
June 2, 2022 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced print ...
June 02, 2022
May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...
May 20, 2022
May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel ...
May 20, 2022
February 16, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, has announced ...
February 16, 2022
Patients With Diabetes Undergoing PCI Have Less Target Lesion Failure With Amphilimus-eluting Stents
November 9, 2021 — Results from SUGAR trial, a randomized, controlled, multicenter trial conducted exclusively in ...
November 09, 2021
October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...
October 20, 2021
September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...
September 01, 2021
June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug ...
June 30, 2021
June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...
June 07, 2021
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized ...
April 14, 2021![Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2]](/sites/default/files/styles/content_feed_medium/public/DES_Comparison_thrombus_formation_Stents_Abbott.jpg?itok=mfh9GUz-)
April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual anti ...
April 06, 2021
January 26, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's Synergy Megatron Drug ...
January 26, 2021
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...
October 29, 2020© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now